The utility and cost of routine follow-up procedures in the surveillance of ovarian and primary peritoneal carcinoma: A 16-year institutional review

British Journal of Cancer

Volumn 103, Issue 11, 2010, Pages 1657-1662

  Rettenmaier, N B ^a   Rettenmaier, C R ^a   Wojciechowski, T ^b   Abaid, L N ^b   Brown III, J V ^b   Micha, J P ^b   Goldstein, B H ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Gynecologic Oncology Associates   (United States)

Author keywords

CA 125; follow up; imaging; ovarian cancer recurrence; physical exam; vaginal cytology

Indexed keywords

CA 125 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; INSTITUTIONAL REVIEW; MAJOR CLINICAL STUDY; OVARY CANCER; PHYSICAL EXAMINATION; PRIMARY PERITONEAL CANCER; PRIORITY JOURNAL; RETROPERITONEAL CANCER; THORAX RADIOGRAPHY; UTERUS CANCER; VAGINA CYTOLOGY;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; COSTS AND COST ANALYSIS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PHYSICAL EXAMINATION; RADIOGRAPHY, THORACIC; TOMOGRAPHY, X-RAY COMPUTED; VAGINAL SMEARS;

EID: 78650192981     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605963     Document Type: Article

References (41)

1. Aletti GD, Powless C, Bakkum-Gamez J, Wilson TO, Podratz KC, Cliby WA (2009) Pattern of retroperitoneal dissemination of primary peritoneum cancer: basis for rational use of lymphadenectomy. Gynecol Oncol 114: 32-36
2. Bast Jr RC, Brewer M, Zou C, Hernandez MA, Daley M, Ozols R, Lu K, Lu Z, Badgwell D, Mills GB, Skates S, Zhang Z, Chan D, Lokshin A, Yu Y (2007) Prevention and early detection of ovarian cancer: mission impossible? Recent Results Cancer Res 174: 91-100
3. Berek JS, Trope C, Vergote I (1999) Surgery during chemotherapy and at relapse of ovarian cancer. Ann Oncol 10: 3-7
4. Bristow RE, Purinton SC, Santillan A, Diaz-Montes TP, Gardner GJ, Giuntoli II RL (2006) Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance. Gynecol Oncol 103: 709-713
5. Casey AC, Park M, Holschneider C, Bozuk M, Punyasavatsut M, Montz FJ (1996) Apical vaginal recurrence of ovarian carcinoma: presentation, treatment and survival. Int J Gynecol Cancer 6: 200-204
6. Chan KK, Tam KF, Tse KY, Ngan HY (2008) The role of regular physical examination in the detection of ovarian cancer recurrence. Gynecol Oncol 110: 158-161
7. Coakley FV, Choi PH, Gougoutas CA, Pothuri B, Venkatraman E, Chi D, Bergman A, Hricak H (2002) Peritoneal metastases: detection with spiral CT in patients with ovarian cancer. Radiology 223: 495-499
8. Eisenhauer EL, Sonoda Y, Levine DA, Abu-Rustum NR, Gemignani ML, Sabbatini PJ, Barakat RR, Chi DS (2008) Platinum resistance and impaired survival in patients with advanced primary peritoneal carcinoma: matched-case comparison with patients with epithelial ovarian carcinoma. Am J Obstet Gynecol 198: 213 e1-e7
9. Eltabbakh GH, Piver MS, Natarajan N, Mettlin CJ (1998) Epidemiologic differences between women with extraovarian primary peritoneal carcinoma and women with epithelial ovarian cancer. Obstet Gynecol 91: 254-259
10. Fader AN, Rose PG (2007) Role of surgery in ovarian carcinoma. J Clin Oncol 25: 2873-2883
11. Fehm T, Heller F, Krämer S, Jäger W, Gebauer G (2005) Evaluation of CA125, physical and radiological findings in follow-up of ovarian cancer patients. Anticancer Res 25: 1551-1554
12. Ferrandina G, Sallustio G, Fagotti A, Vizzielli G, Paglia A, Cucci E, Margariti A, Aquilani L, Garganese G, Scambia G (2009) Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduc-tion in advanced ovarian cancer: a prospective trial. Br J Cancer 101: 1066-1073
13. Funt SA, Hricak H, Abu-Rustum N, Mazumdar M, Feldman H, Chi DS (2004) Role of CT in the management of recurrent ovarian cancer. AJR Am J Roentgenol 182: 393-398
14. Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR (2004) Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother 58: 24-38
15. Gadducci A, Cosio S, Conte PF, Genazzani AR (2005) Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature. Crit Rev Oncol Hematol 55: 153-166
16. Gadducci A, Cosio S, Zola P, Landoni F, Maggino T, Sartori E (2007) Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature. Int J Gynecol Cancer 17: 21-31
17. Gadducci A, Sartori E, Maggino T, Zola P, Landoni F, Fanucchi A, Palai N, Alessi C, Ferrero AM, Cosio S, Cristofani R (1998) Analysis of failures after negative second-look in patients with advanced ovarian cancer: an Italian multicenter study. Gynecol Oncol 68: 150-155
18. García-Velloso MJ, Jurado M, Ceamanos C, Aramendía JM, Garrastachu MP, López-García G, Richter JA (2007) Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma. Eur J Nucl Med Mol Imaging 34: 1396-1405
19. Gu P, Pan LL, Wu SQ, Sun L, Huang G (2009) CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur J Radiol 71: 164-174
20. Havrilesky LJ, Sanders GD, Kulasingam S, Myers ER (2008) Reducing ovarian cancer mortality through screening: is it possible, and can we afford it? Gynecol Oncol 111: 179-187
21. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43-66
22. Lee DW, Foster DA (2009) The association between hospital outcomes and diagnostic imaging: early findings. J Am Coll Radiol 6: 780-785
23. Menczer J, Chetrit A, Sadetzki S, Golan A, Levy T (2006) Follow-up of ovarian and primary peritoneal carcinoma: the value of physical examination in patients with pretreatment elevated CA125 levels. Gynecol Oncol 103: 137-140
24. Milam MR, Sood AK, King S, Bassett Jr RL, Lu KH, Slomovitz BM, Coleman RL, Ramirez PT (2007) Supracervical hysterectomy in patients with advanced epithelial ovarian cancer. Obstet Gynecol 109: 641-646
25. Murakami M, Miyamoto T, Iida T, Tsukada H, Watanabe M, Shida M, Maeda H, Nasu S, Yasuda S, Yasuda M, Ide M (2006) Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer. Int J Gynecol Cancer 16: 99-107
26. NIH (1994) Ovarian cancer: screening, treatment, and follow-up. NIH Consensus Statement 12: 1-30
27. Patsner B, Orr Jr JW, Mann Jr WJ, Taylor PT, Partridge E, Allmen T (1990) Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease? Gynecol Oncol 38: 373-376
28. Rettenmaier MA, Goldstein BH, Stallman JM, Brown III JV, Micha JP (2005) Greatly elevated serum CA-125 level in a patient with a ruptured endometrioma. J Gynecol Surg 21: 109-112
29. Rossing MA, Wicklund KG, Cushing-Haugen KL, Weiss NS (2010) Predictive value of symptoms for early detection of ovarian cancer. J Natl Cancer Inst 102: 222-229
30. Rustin GJ, Marples M, Nelstrop AE, Mahmoudi M, Meyer T (2001) Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 19: 4054-4057
31. Rustin GJ, van der Burg ME (2009) A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators. J Clin Oncol 27: 18s
32. Santillan A, Govan L, Zahurak ML, Diaz-Montes TP, Giuntoli II RL, Bristow RE (2008) Feasibility and economic impact of a clinical pathway for pap test utilization in Gynecologic Oncology practice. Gynecol Oncol 109: 388-393
33. Sebastian S, Lee SI, Horowitz NS, Scott JA, Fischman AJ, Simeone JF, Fuller AF, Hahn PF (2008) PET-CT vs. CT alone in ovarian cancer recurrence. Abdom Imaging 33: 112-118
34. Sugiyama T, Nishida T, Komai K, Nishimura H, Yakushiji M, Nishimura H (1996) Comparison of CA 125 assays with abdominopelvic computed tomography and transvaginal ultrasound in monitoring of ovarian cancer. Int J Gynaecol Obstet 54: 251-256
35. Torizuka T, Nobezawa S, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, Takekuma M, Maeda M, Ouchi Y (2002) Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose. Eur J Nucl Med Mol Imaging 29: 797-803
36. U.S. Preventive Services Task Force (1996) Guide to Clinical Preventive Services (2nd edn). National Institute of Health: Washington, DC
37. Vaidya AP, Curtin JP (2003) The follow-up of ovarian cancer. Semin Oncol 30: 401-412
38. van Nagell Jr JR, DePriest PD, Ueland FR, DeSimone CP, Cooper AL, McDonald JM, Pavlik EJ, Kryscio RJ (2007) Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer 109: 1887-1896
39. von Georgi R, Schubert K, Grant P, Münstedt K (2004) Post-therapy surveillance and after-care in ovarian cancer. Eur J Obstet Gynecol Reprod Biol 114: 228-233
40. Wilson CM, Tobin S, Young RC (2004) The exploding worldwide cancer burden: the impact of cancer on women. Int J Gynecol Cancer 14: 1-11
41. Zola P, Fuso L, Mazzola S, Gadducci A, Landoni F, Maggino T, Sartori E (2007) Follow-up strategies in gynecological oncology: searching appropriateness. Int J Gynecol Cancer 17: 1186-1193